<DOC>
	<DOCNO>NCT00282503</DOCNO>
	<brief_summary>The purpose study compare safety efficacy ECP treatment combine high dose corticosteroid versus high dose corticosteroid alone , treatment patient newly diagnose acute GvHD ( Grades II III ) develop within 100 day follow allo HPCT .</brief_summary>
	<brief_title>Extracorporeal Photoimmune Therapy With UVADEX Treatment Acute Graft Versus-Host Disease</brief_title>
	<detailed_description />
	<mesh_term>Graft v Host Disease</mesh_term>
	<mesh_term>Prednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone</mesh_term>
	<mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
	<mesh_term>Prednisolone</mesh_term>
	<mesh_term>Prednisolone hemisuccinate</mesh_term>
	<mesh_term>Prednisolone phosphate</mesh_term>
	<mesh_term>Methoxsalen</mesh_term>
	<criteria>1 . Signed informed consent must obtain prior conduct study procedure . 2 . Patients must great equal 18 year old weigh great equal 40 kg ( 88 lb ) . 3 . Patients must receive allogeneic hematopoietic BMT PBSCT myeloablative reducedintensity condition new onset acute GvHD , Grades II III , include skin develop within 100 day follow alloHPCT . 4 . Patients must receive allogeneic hematopoietic BMT PBSCT relate unrelated donor match minimum HLAA , B , DR locus ( i.e. , least 6 6 match ) . HLAA B match determine serologic testing , HLADR match molecular method . 5 . Patients must receive calcineurin inhibitor study entry part acute GvHD prophylactic regimen . Patients may receive additional immunosuppressant acute GvHD prophylaxis prior study entry . 6 . Patients must Karnofsky performance great equal 50 . 7 . Patients must able willing comply study procedure . 8 . Patients must receive , must receive , first corticosteroid dose approximately 2.0 mg/kg/day 2.5 mg/kg/day ( methylprednisolone equivalent ) within 24 hour initial diagnosis Grade II III acute GvHD . ( Up 2.5 mg/kg/day allow inadvertent dose fluctuation reason lack response . ) 9 . Female patient must one following : postmenopausal , surgically incapable bearing child , practice acceptable method birth control ( acceptable method include hormonal contraceptive , intrauterine device , spermicide barrier ) . Abstinence partner/spouse sterility may also qualify Investigator 's discretion . If female patient childbearing potential , must negative urine pregnancy test screening . Male patient must also commit use adequate contraceptive precaution ( condom ) . All patient ( male females childbearing potential ) must commit use adequate contraceptive precaution throughout participation study least 3 month follow last ECP treatment . 1 . Patients diagnose chronic GvHD , include de novo chronic GvHD , prior 100 day follow alloHPCT . 2 . Patients receive donor lymphocyte infusion . 3 . Patients uncontrolled lifethreatening infection . 4 . Patients white blood cell ( WBC ) count &lt; 1.5 x 10^9/L ( 1,500/mcL ) . 5 . Patients platelet count &lt; 20.0 x 10^9/L ( 20,000/mcL ) , despite platelet transfusion . 6 . Patients whose total bilirubin great equal 22 mg/dL . 7 . Patients International Normalized Ratio ( INR ) great equal 2 . 8 . Patients enrol concomitant investigation treatment acute GvHD . 9 . Patients unable tolerate extracorporeal volume shift associate ECP treatment due presence follow condition : uncompensated congestive heart failure , pulmonary edema , severe chronic obstructive pulmonary disease , severe asthma , renal failure , hepatic encephalopathy , hepatorenal syndrome . 10 . Female patient whose hemoglobin ( Hgb ) &lt; 8.5 g/dL male patient whose Hgb &lt; 10.0 g/dL screening , despite pack red blood cell transfusion . 11 . Patients poor tolerability venipuncture lack adequate venous access require treatment blood sampling . 12 . Patients know hypersensitivity allergy Oxsoralen ( methoxsalen ) . 13 . Patients know hypersensitivity allergy heparin citrate product . 14 . Female patient pregnant and/or lactating . 15 . Patients coexist melanoma , basal cell squamous cell skin carcinoma , aphakia , photosensitive disease ( e.g. , porphyria , systemic lupus erythematosus , albinism ) , white blood cell count &gt; 25,000 cells/mm3 , previous splenectomy , coagulation disorder .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>aGvHD</keyword>
</DOC>